Literature DB >> 21606534

Hepatitis C virus infection and hepatic stellate cell activation downregulate miR-29: miR-29 overexpression reduces hepatitis C viral abundance in culture.

Sarmistha Bandyopadhyay1, Robin C Friedman, Rebecca T Marquez, Kathy Keck, Benjamin Kong, Michael S Icardi, Kyle E Brown, Christopher B Burge, Warren N Schmidt, Yulei Wang, Anton P McCaffrey.   

Abstract

BACKGROUND: Chronic hepatitis C virus (HCV)-induced liver fibrosis involves upregulation of transforming growth factor (TGF)-β and subsequent hepatic stellate cell (HSC) activation. MicroRNAs (miRNAs) regulate HCV infection and HSC activation.
METHODS: TaqMan miRNA profiling identified 12 miRNA families differentially expressed between chronically HCV-infected human livers and uninfected controls. To identify pathways affected by miRNAs, we developed a new algorithm (pathway analysis of conserved targets), based on the probability of conserved targeting.
RESULTS: This analysis suggested a role for miR-29 during HCV infection. Of interest, miR-29 was downregulated in most HCV-infected patients. miR-29 regulates expression of extracellular matrix proteins. In culture, HCV infection downregulated miR-29, and miR-29 overexpression reduced HCV RNA abundance. miR-29 also appears to play a role in HSCs. Hepatocytes and HSCs contribute similar amounts of miR-29 to whole liver. Both activation of primary HSCs and TGF-β treatment of immortalized HSCs downregulated miR-29. miR-29 overexpression in LX-2 cells decreased collagen expression and modestly decreased proliferation. miR-29 downregulation by HCV may derepress extracellular matrix synthesis during HSC activation.
CONCLUSIONS: HCV infection downregulates miR-29 in hepatocytes and may potentiate collagen synthesis by reducing miR-29 levels in activated HSCs. Treatment with miR-29 mimics in vivo might inhibit HCV while reducing fibrosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21606534      PMCID: PMC3143452          DOI: 10.1093/infdis/jir186

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  45 in total

1.  Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.

Authors:  Benjamin P Lewis; Christopher B Burge; David P Bartel
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

2.  Suppression of type I collagen production by microRNA-29b in cultured human stellate cells.

Authors:  Tomohiro Ogawa; Masashi Iizuka; Yumiko Sekiya; Katsutoshi Yoshizato; Kazuo Ikeda; Norifumi Kawada
Journal:  Biochem Biophys Res Commun       Date:  2009-11-12       Impact factor: 3.575

3.  Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma.

Authors:  Shunsuke Ura; Masao Honda; Taro Yamashita; Teruyuki Ueda; Hajime Takatori; Ryuhei Nishino; Hajime Sunakozaka; Yoshio Sakai; Katsuhisa Horimoto; Shuichi Kaneko
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

4.  miR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell: An essential role for apoptosis.

Authors:  Can-Jie Guo; Qin Pan; Ding-Guo Li; Hua Sun; Bo-Wei Liu
Journal:  J Hepatol       Date:  2009-02-02       Impact factor: 25.083

5.  Gene expression profiles during hepatic stellate cell activation in culture and in vivo.

Authors:  Samuele De Minicis; Ekihiro Seki; Hiroshi Uchinami; Johannes Kluwe; Yonghui Zhang; David A Brenner; Robert F Schwabe
Journal:  Gastroenterology       Date:  2007-02-21       Impact factor: 22.682

6.  Interferon modulation of cellular microRNAs as an antiviral mechanism.

Authors:  Irene M Pedersen; Guofeng Cheng; Stefan Wieland; Stefano Volinia; Carlo M Croce; Francis V Chisari; Michael David
Journal:  Nature       Date:  2007-10-18       Impact factor: 49.962

7.  Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival.

Authors:  Jinmai Jiang; Yuriy Gusev; Ileana Aderca; Teresa A Mettler; David M Nagorney; Daniel J Brackett; Lewis R Roberts; Thomas D Schmittgen
Journal:  Clin Cancer Res       Date:  2008-01-15       Impact factor: 12.531

8.  Distribution of organelles and membranes between hepatocytes and nonhepatocytes in the rat liver parenchyma. A stereological study.

Authors:  A Blouin; R P Bolender; E R Weibel
Journal:  J Cell Biol       Date:  1977-02       Impact factor: 10.539

Review 9.  Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets.

Authors:  A M Gressner; R Weiskirchen
Journal:  J Cell Mol Med       Date:  2006 Jan-Mar       Impact factor: 5.310

10.  Identification of keratinocyte growth factor as a target of microRNA-155 in lung fibroblasts: implication in epithelial-mesenchymal interactions.

Authors:  Nicolas Pottier; Thomas Maurin; Benoit Chevalier; Marie-Pierre Puisségur; Kevin Lebrigand; Karine Robbe-Sermesant; Thomas Bertero; Christian L Lino Cardenas; Elisabeth Courcot; Géraldine Rios; Sandra Fourre; Jean-Marc Lo-Guidice; Brice Marcet; Bruno Cardinaud; Pascal Barbry; Bernard Mari
Journal:  PLoS One       Date:  2009-08-24       Impact factor: 3.240

View more
  67 in total

1.  MicroRNA profiling identifies miR-29 as a regulator of disease-associated pathways in experimental biliary atresia.

Authors:  Nicholas J Hand; Amber M Horner; Zankhana R Master; LaTasha A Boateng; Claire LeGuen; Marina Uvaydova; Joshua R Friedman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-02       Impact factor: 2.839

Review 2.  RNA viruses and microRNAs: challenging discoveries for the 21st century.

Authors:  Gokul Swaminathan; Julio Martin-Garcia; Sonia Navas-Martin
Journal:  Physiol Genomics       Date:  2013-09-17       Impact factor: 3.107

3.  Hepatitis C virus infection stimulates transforming growth factor-β1 expression through up-regulating miR-192.

Authors:  Ji Hyun Kim; Chang Ho Lee; Seong-Wook Lee
Journal:  J Microbiol       Date:  2016-06-28       Impact factor: 3.422

4.  Serum microRNA panels as potential biomarkers for early detection of hepatocellular carcinoma on top of HCV infection.

Authors:  Abdel-Rahman Nabawy Zekri; Amira Salah El-Din Youssef; Eman Desouky El-Desouky; Ola Sayed Ahmed; Mai M Lotfy; Auhood Abdel-Monem Nassar; Abeer A Bahnassey
Journal:  Tumour Biol       Date:  2016-06-06

5.  Hepatitis C Virus Mediated Inhibition of miR-181c Activates ATM Signaling and Promotes Hepatocyte Growth.

Authors:  Tapas Patra; Keith Meyer; Ratna B Ray; Ranjit Ray
Journal:  Hepatology       Date:  2019-11-03       Impact factor: 17.425

6.  Serum microRNA expression profile as a biomarker for the diagnosis of pertussis.

Authors:  Yiyue Ge; Kangchen Zhao; Yuhua Qi; Xiaoyan Min; Zhiyang Shi; Xian Qi; Yunfeng Shan; Lan Cui; Minghao Zhou; Yong Wang; Hua Wang; Lunbiao Cui
Journal:  Mol Biol Rep       Date:  2012-10-18       Impact factor: 2.316

Review 7.  MicroRNA and hepatitis C virus--challenges in investigation and translation: a review of the literature.

Authors:  Paul Ravi Waldron; Mark Holodniy
Journal:  Diagn Microbiol Infect Dis       Date:  2014-06-05       Impact factor: 2.803

8.  MiR-29a Assists in Preventing the Activation of Human Stellate Cells and Promotes Recovery From Liver Fibrosis in Mice.

Authors:  Yoshinari Matsumoto; Saori Itami; Masahiko Kuroda; Katsutoshi Yoshizato; Norifumi Kawada; Yoshiki Murakami
Journal:  Mol Ther       Date:  2016-06-23       Impact factor: 11.454

9.  MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells.

Authors:  Takayoshi Shirasaki; Masao Honda; Tetsuro Shimakami; Rika Horii; Taro Yamashita; Yoshio Sakai; Akito Sakai; Hikari Okada; Risa Watanabe; Seishi Murakami; MinKyung Yi; Stanley M Lemon; Shuichi Kaneko
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

10.  Toll-like receptor 3-activated macrophages confer anti-HCV activity to hepatocytes through exosomes.

Authors:  Yu Zhou; Xu Wang; Li Sun; Li Zhou; Tong-Cui Ma; Li Song; Jian-Guo Wu; Jie-Liang Li; Wen-Zhe Ho
Journal:  FASEB J       Date:  2016-09-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.